相关实验视频

Updated: Jan 14, 2026

Author Spotlight: Obtaining High-Quality CSF and Blood Samples for Epilepsy Biomarker Discovery

Author Spotlight: Obtaining High-Quality CSF and Blood Samples for Epilepsy Biomarker Discovery

Published on: September 1, 2023

功能和血红蛋白独立地预测了患者的勒维拉暴露:多因素回归研究

Xuehui Jiang¹, Fangfang Xiong², Zhihang Lin¹

¹Department of Pharmacy, Quanzhou First Hospital Affiliated to Fujian Medical University, Quanzhou, 362000, People's Republic of China.

Drug design, development and therapy

|October 23, 2025

概括

肌素清除和血红蛋白水平显著影响患者的 levetiracetam (LEV) 药物暴露. 这项研究开发了一个模型来预测LEV度,有助于个性化剂量,特别是在药物监测有限的地方.

科学领域:

药理动力学和药理动力学
临床药房临床药房
症管理症管理

背景情况:

列维 (LEV) 是一种广泛使用的抗药物,其度在血中具有显著的个体间变化.
了解影响LEV稳定状态低度的因素对于优化治疗疗效和最大限度地减少不良影响至关重要.
预测模型可以帮助实现目标LEV度,特别是在治疗药物监测机会有限的环境中.

研究的目的:

在患者中确定影响莱维他 (LEV) 血度的关键因素.
开发和验证LEV稳定状态低谷度 (C/D) 的预测模型.

主要方法:

对来自130名患者的临床数据进行了回顾性分析,其中包括175个LEV稳定状态最低度样本.
单变量分析和多重线性回归建模,以评估人口统计学,生化学和同时服用药物的因素的影响.
引导验证 (1000 resamples) 来确认模型的稳定性和系数稳定性.

主要成果:

肌素清除率 (Ccr) 是最强的独立预测因子,Ccr的降低与LEV C/D的增加有关 (非标准化β = -0.168,p < 0.001).
血红蛋白 (HGB) 显示出二次负相关性,其中较低的HGB水平与较高的LEV C/D相关 (非标准化的β = -0.070,p <0.05).
最终的预测方程 (C/Dpred = 37.759 - 0.168 × Ccr - 0.070 × HGB) 解释了LEV C/D中44.0%的差异 (调整后R2 = 0.440,p < 0.001).

结论:

常规临床指标Ccr和HGB是患者LEV暴露的重要决定因素.
开发的预测模型为LEV的药理动力学变化提供了洞察力,并可以支持个性化的剂量策略.
进一步的外部验证和前性的多中心研究是必要的,以确认预测模型的通用性.

关键词:

肌素的清除率是什么是一种.血红蛋白血红蛋白是一个莱维泰拉塞坦 ( levetiracetam) 的使用情况多因素回归的多因素回归.

更多相关视频

Microdialysis of Excitatory Amino Acids During EEG Recordings in Freely Moving Rats

Microdialysis of Excitatory Amino Acids During EEG Recordings in Freely Moving Rats

Published on: November 8, 2018

A Model for Epilepsy of Infectious Etiology using Theiler's Murine Encephalomyelitis Virus

A Model for Epilepsy of Infectious Etiology using Theiler's Murine Encephalomyelitis Virus

Published on: June 23, 2022

相关概念视频

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...

Drug Dosing in Renal Diseases: Estimation of Glomerular Filtration Rate Based on Serum Creatinine Concentration

Drug Dosing in Renal Diseases: Estimation of Glomerular Filtration Rate Based on Serum Creatinine Concentration

Glomerular filtration rate (GFR) can be estimated from serum creatinine using the modification of diet in renal disease (MDRD) formula or the chronic kidney disease–epidemiology collaboration (CKD–EPI) equation. Both methods are widely used in clinical practice to assess kidney function and guide treatment decisions.The MDRD equation does not require weight or height measurements and is normalized to the body surface area of 1.73 m², considered the average adult surface area.

Epilepsy and Seizures: Overview

Epilepsy and Seizures: Overview

Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...

Antiepileptic Drugs: Potassium Channel Activators

Antiepileptic Drugs: Potassium Channel Activators

Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...

Hepatic Drug Excretion: Influencing Factors

Hepatic Drug Excretion: Influencing Factors

The biliary system of the liver, crucial for bile secretion and drug excretion, comprises intrahepatic bile ducts that merge to form the common hepatic duct. This duct, carrying hepatic bile, combines with the cystic duct, draining the gallbladder and forming the common bile duct, which empties into the duodenum. Bile, produced by hepatic cells lining the bile canaliculi, is composed primarily of water, bile salts, pigments, electrolytes, and lesser amounts of cholesterol and fatty acids. Bile...

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Excretion

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Excretion

In geriatric patients, renal physiology undergoes significant changes, including diminished renal blood flow and a lower glomerular filtration rate (GFR), leading to alterations in medication clearance. Drugs such as aminoglycoside antibiotics, lithium, and digoxin, which rely on glomerular filtration for removal from the body, particularly impact pharmacokinetics. These drugs tend to have slower clearance rates in older adults, necessitating careful dosage considerations.Evaluation of renal...